Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 23, 2023

Ramucirumab Plus Erlotinib for Previously Untreated EGFR-Mutated Metastatic NSCLC



Additional Info

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
ESMO Open 2023 Jun 28;8(4)101580, EB Garon, M Reck, K Nishio, JV Heymach, M Nishio, S Novello, L Paz-Ares, S Popat, SP Aix, H Graham, BD Butts, C Visseren-Grul, K Nakagawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading